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ABSTRACT
Introduction: This publication adds
perspective to a recent publication by Johal
et al. that presented the performance of
combination inhalation therapies at a flow
rate differing from that recommended by the
regulatory authorities for metered dose inhaler
(MDI) performance testing. Altering the flow
rate through an impactor can create potential
pitfalls which can result in performance
misrepresentation.
Performance Testing of MDIs at Non-Standard
Flow Rates: In-house data for Foster (Chiesi,
Parma, Italy) and Flutiform (Bard
Pharmaceuticals Limited, Cambridge, UK) have
been collected using standard pharmacopaeial
conditions and also at the unconventional
60 L/min flow rate utilized by Johal et al.
A marked reduction in mass median
aerodynamic diameters (MMADs) of both the
inhaled corticosteroids (ICS) and long-acting
beta agonists in Foster MDI from approximately
1.2–0.5 lm with increase in flow rate (Johal
et al.) is not observed. Use of the Andersen
cascade impactor at flow rates above 28.3 L/min
is not common practice. The industry generally
utilizes data from the next generation impactor
(NGI), an impactor specifically designed and
developed for this purpose. Data for the ICS
component of Foster have been generated using
an NGI operated at 30 and 60 L/min, yielding
an MMAD (±SD) of 1.1 ± 0.1 lm at both flow
rates.
Therapeutic Significance of Submicron
Particles: Johal et al. suggest that submicron
particles are prone to be exhaled by the patient,
and therefore imply that they may be non-
effective. However, therapeutic significance of
submicron particles is supported by a
scintigraphic lung deposition study carried out
using the Foster MDI. The in vivo data highlight
that just 2–3% of the nominal dose was exhaled,
with 31–34% deposited in the lungs.
Conclusion: Consistent particle size
distribution of both active drug components
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delivered from Foster MDI at flow rates of 28–30
and 60 L/min is observed.
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INTRODUCTION
Characterization of the performance of metered
dose inhalers (MDIs) by cascade impaction is a
complex procedure, requiring the pertinent
selection of many experimental and
environmental variables in order to achieve
realistic and relevant results. Examples have
been published illustrating that MDI delivery
performance variability may occur under
extreme ambient conditions [1–3].
No less crucial is appropriate analysis of the
resulting data in order to calculate accurate
values for performance indicators such as mass
median aerodynamic diameter (MMAD) and
fine particle dose (FPD) [4]. Industry approved
software is available to facilitate the appropriate
processing of experimental data in accordance
with regulatory guidelines (CITDAS V3.10,
Copley Scientific, Nottingham, UK).
This publication adds perspective to a recent
publication by Johal et al. [5] that presented
performance of combination inhalation
therapies at a flow rate, 60 L/min., differing
from that recommended by regulatory
authorities for Metered Dose Inhaler
performance testing, 28.3 L/min [United States
Pharmacopeia (USP) 36]. Altering the flow rate
through an impactor can create potential
pitfalls, including impactor choice and
preparation (i.e., plate coating) and data
processing parameters, which can result in
performance misrepresentation [2–4, 6–9].
This review article does not contain any
studies with human or animal subjects
performed by any of the authors.
PERFORMANCE TESTING OF MDIS
AT NON-STANDARD FLOW RATES
Johal et al. [5] utilized a dosing procedure that,
seemingly, is non-compliant with the patient
instruction leaflet [10]. Furthermore, it is
known that a combination of low dose
number and uncoated impactor plates results
in the underestimation of particle size
information [2, 3, 6, 7]. In addition, figure two
of the Johal et al. [5] paper utilizes identical
impactor stage cut-off diameters for the
Andersen Cascade Impactor (ACI), at both
28.3 and 60 L/min sampling flow rates, rather
than calculating precise stage cut-off diameters
and appropriately representing the data [8, 9].
Table 1 presents our in-house data for Foster
(Beclometasone dipropionate and Formoterol
Fumarate, Chiesi, Parma, Italy) and Flutiform
(Fluticasone propionate and Formoterol
Fumarate, Bard Pharmaceuticals Limited,
Cambridge, UK) collected using standard
pharmacopaeial conditions and also at the
unconventional 60 L/min flow rate utilized by
Johal et al. [5]. The data in Table 1 have been
processed with ACI stage cut-off diameters in
accordance with Van Oort et al. [9]. A marked
reduction in MMADs of both the inhaled
corticosteroids (ICS) and long-acting beta
agonists (LABA) in Foster MDI from
approximately 1.2–0.5 lm with increase in
flow rate (Johal et al. [5]), which permits a
potential misrepresentation of the product’s
characteristics, is not observed. Furthermore,
careful inspection of the cumulative fractional
frequency–LABA particle size distribution
curves presented in figure 2d of their paper [5],
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would suggest that MMADs derived from these
plots are consistent with those shown in
Table 1. The Geometric Standard Deviation
observed for the 60 L/min Foster in-house data
was 1.8, well below the surprising high value of
5.3 reported by Johal et al. [5].
Use of the ACI at flow rates above 28.3 L/min
is not common practice [8, 9]. The industry
generally utilizes data from the next generation
impactor (NGI; USP 36, Apparatus 6), an
impactor specifically designed and developed
for this purpose [11]. In-house data for the ICS
component of Foster have been generated using
an NGI operated at 30 and 60 L/min yielding an
MMAD (±SD) of 1.1 ± 0.1 lm at both flow rates.
The equivalence of the particle size distributions
for the ICS and LABA components emitted from
Foster has previously been published [12].
Johal et al. [5] report all fine particle drug
delivery data normalized to nominal label claim
rather than using the accepted pharmacopoeial
approach of calculation against drug mass (dose),
delivered to the ACI, ex-actuator, nor is it
confirmed that drug mass balance against
experimental delivered dose uniformity was
achieved (USP 36), which is unhelpful.
Furthermore, reporting that Flutiform has a
higher and more consistent fine particle fraction
(FPF) than Foster is potentially misleading, firstly,
because the ICS components are chemically and
physically different and formulated at different
concentrations, and secondly, our in-house data
generated by NGI at 30 L/min show the converse
as follows: Flutiform (FP as particulate
suspension)—FPD = 39 ± 4 lg, FPF (as fraction
of delivered dose) 37 ± 4%; Foster (BDP as
solution)—FPD = 34 ± 2 lg, FPF 40 ± 2%. The
corresponding NGI data obtained at 60 L/min
are Flutiform: FPD = 39 ± 3 lg, FPF = 34 ± 1%;
Foster; FPD = 47 ± 2 lg, FPF = 54 ± 2%.
THERAPEUTIC SIGNIFICANCE
OF SUBMICRON PARTICLES
Johal et al. [5] suggest that submicron particles
are prone to be exhaled by the patient, and
therefore imply that they may be non-effective.
However, studies exist which contradict such a
claim [13–16]. Extra-fine particles have been
demonstrated to show high central and
peripheral deposition within the lung, as
particle diffusion processes become more
dominant when particle size decreases [15].
Therapeutic significance of submicron particles
is supported by a scintigraphic lung deposition
study carried out using the Foster MDI [13]. The
in vivo data highlight that just 2–3% of the
nominal dose was exhaled, with 31–34%
deposited in the lungs.
The testing of MDIs at alternative flow rates is
not a common practice in the pharmaceutical
industry: the majority of patient instruction
leaflets, including those for Foster [10] and
Flutiform [17], advocate a long, slow breath
when a dose is administered; for example:
‘‘breathe in slowly and deeply’’; ‘‘hold your
breath for as long as possible’’. The patient is
also directed not to perform the process ‘‘too
quickly’’.
Table 1 MMAD values (n C 6) for Foster and Flutiform
delivered to ACI at alternative ﬂow rates
Product MMAD (lm) – standard deviation
28.3 L/min 60.0 L/min
Foster
BDP 1.3 ± 0.1 1.2 ± 0.2
FF 1.4 ± 0.2 1.2 ± 0.2
Flutiform
FP 4.0 ± 0.1 3.6 ± 0.1
FF 3.6 ± 0.1 3.2 ± 0.2
ACI Andersen cascade impactor, BDP beclometasone
dipropionate, FF formoterol fumarate, FP ﬂuticasone
propionate, MMAD mass median aerodynamic diameter
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Figure 1 demonstrates that for subjects with
alternative breath capabilities, similar drug
deposition is obtained, highlighting the
robustness of Foster MDI drug in vivo delivery
performance for both healthy and injured
lungs. Analysis of 8 patients with asthma and
8 healthy subjects showed a lung deposition of
30.9 ± 8.9 and 34.1 ± 9.3% of the nominal
dose, respectively [13]. This in vivo lung
deposition correlates well with published
in vitro data of 35 ± 1% of nominal dose [12].
CONCLUSION
Consistent particle size distribution of both
active drug components delivered from Foster
MDI at flow rates of 28–30 and 60 L/min is
observed.
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Fig. 1 Scintigraphic image of healthy subject and asthma patient after a single inhalation of four puffs of Foster (BDP/FF;
100/6), metered dose inhaler. BDP beclometasone dipropionate, FF formoterol fumarate
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